Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MaxCyte Inc (MXCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MXCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.68
1 Year Target Price $6.68
| 6 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.82% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 148.18M USD | Price to earnings Ratio - | 1Y Target Price 6.68 |
Price to earnings Ratio - | 1Y Target Price 6.68 | ||
Volume (30-day avg) 6 | Beta 0.27 | 52 Weeks Range 1.26 - 5.20 | Updated Date 08/29/2025 |
52 Weeks Range 1.26 - 5.20 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.1 | Actual -0.12 |
Profitability
Profit Margin -125.22% | Operating Margin (TTM) -167.24% |
Management Effectiveness
Return on Assets (TTM) -14.19% | Return on Equity (TTM) -21.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40128240 | Price to Sales(TTM) 4.14 |
Enterprise Value 40128240 | Price to Sales(TTM) 4.14 | ||
Enterprise Value to Revenue 1.12 | Enterprise Value to EBITDA -11.07 | Shares Outstanding 106607000 | Shares Floating 96174121 |
Shares Outstanding 106607000 | Shares Floating 96174121 | ||
Percent Insiders 1.78 | Percent Institutions 75.31 |
Upturn AI SWOT
MaxCyte Inc
Company Overview
History and Background
MaxCyte, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland. It is a global cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research, development, and commercialization of novel cell therapies.
Core Business Areas
- Cell Engineering Platform: MaxCyte's core technology centers around its flow electroporation platform, enabling complex cell engineering to support the discovery, development, manufacturing and commercialization of a new generation of cell-based medicines.
- Partnerships: MaxCyte partners with biopharmaceutical companies to enable their cell therapy programs and receives licensing fees, milestone payments, and royalties based on the clinical and commercial success of their partners' programs.
Leadership and Structure
MaxCyte is led by a board of directors and a management team. The CEO is Maarten Persoon. The organizational structure includes departments focused on research, development, manufacturing, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- ExPERT platform: The ExPERT platform is MaxCyte's core technology. It enables the delivery of a broad range of molecules, including DNA, RNA, CRISPR/Cas9 ribonucleoproteins, and proteins, into cells with high efficiency and viability. Competitors include Lonza, Thermo Fisher Scientific, and Miltenyi Biotec. MaxCyte generates revenue from instrument sales, cell processing assemblies (CPAs), and service contracts.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy, gene editing, and regenerative medicine. There is a high demand for cell engineering technologies to develop and manufacture cell therapies.
Positioning
MaxCyte is a leading provider of cell engineering technology in the cell therapy market. Its flow electroporation platform offers several advantages, including high efficiency, scalability, and versatility.
Total Addressable Market (TAM)
The total addressable market is estimated to be billions of dollars. MaxCyte is positioned to capture a significant share of the market through its strategic partnerships and continued innovation.
Upturn SWOT Analysis
Strengths
- Proprietary flow electroporation technology
- Strong partnerships with leading biopharmaceutical companies
- Scalable and versatile platform
- Experienced management team
Weaknesses
- Dependence on partner programs for revenue
- Limited number of commercialized products
- High operating expenses
- Susceptible to changes in regulatory environment for cell therapies
Opportunities
- Expansion of partnerships
- Development of new cell therapy applications
- Geographic expansion
- Acquisitions
Threats
- Competition from other cell engineering technologies
- Regulatory hurdles
- Clinical trial failures of partner programs
- Economic downturns
Competitors and Market Share
Key Competitors
- LONZA.SW
- TMO
- MILT.DE
Competitive Landscape
MaxCyte's competitive advantage lies in its proprietary flow electroporation technology, which enables high efficiency and scalability. However, it faces competition from other cell engineering technologies, such as viral transduction and lipofection.
Growth Trajectory and Initiatives
Historical Growth: MaxCyte's historical growth has been driven by its increasing number of partnerships and the clinical progress of its partners' programs.
Future Projections: Future growth projections are dependent on the progress of ongoing clinical trials and new partnerships. Analyst estimates can be found in financial reports.
Recent Initiatives: Recent strategic initiatives include expansion of manufacturing capacity, new partnerships, and development of new cell therapy applications.
Summary
MaxCyte is a cell engineering company with a proprietary platform and partnerships with biopharmaceutical companies. Its success depends on the clinical progress of partner programs. It needs to expand its number of approved products, as revenues largely depend on companies who have approved the technology. Its strength lies in its unique technology that could lead to better clinical solutions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MaxCyte Investor Relations
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. The information is based on available data and analysis and is subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MaxCyte Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2021-07-30 | President, CEO & Executive Director Mr. Maher Masoud | ||
Sector Healthcare | Industry Medical Devices | Full time employees 114 | Website https://www.maxcyte.com |
Full time employees 114 | Website https://www.maxcyte.com | ||
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.